AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

In a statement, Illinois-based AbbVie said the studies did not show a statistically significant improvement in patients using the medicine, emraclidine, as a once-daily oral monotherapy.

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were ...

AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.

Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of therapy ...

In other recent news, AbbVie received FDA approval for MAVYRET, now the first oral treatment for acute hepatitis C, expanding its use to both adults and children.